• Je něco špatně v tomto záznamu ?

Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up

M. Bruzova, R. Rusina, Z. Stejskalova, R. Matej

. 2021 ; 11 (1) : 10837. [pub] 20210525

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004326

Various proteins play a decisive role in the pathology of different neurodegenerative diseases. Nonetheless, most of these proteins can only be detected during a neuropathological assessment, although some non-specific biomarkers are routinely tested for in the cerebrospinal fluid (CSF) as a part of the differential diagnosis of dementia. In antemortem CSF samples from 117 patients with different types of neuropathologically confirmed neurodegenerative disease with dementia, we assessed total-tau (t-tau), phosphorylated-tau (181P) (p-tau), amyloid-beta (1-42) (Aβ42), TAR DNA binding protein (TDP)-43, progranulin (PGRN), and neurofilament light (NfL) chain levels, and positivity of protein 14-3-3. We found t-tau levels and the t-tau/p-tau ratios were significantly higher in prion diseases compared to the other neurodegenerative diseases. Statistically significant differences in the t-tau/Aβ42 ratio predominantly corresponded to t-tau levels in prion diseases and Aβ42 levels in AD. TDP-43 levels were significantly lower in prion diseases. Additionally, the TDP-43/Aβ42 ratio was better able to distinguish Alzheimer's disease from other neurodegenerative diseases compared to using Aβ42 alone. In frontotemporal lobar degeneration, PRGN levels were significantly higher in comparison to other neurodegenerative diseases. There is an increasing need for biomarkers suitable for diagnostic workups for neurodegenerative diseases. It appears that adding TDP-43 and PGRN to the testing panel for neurodegenerative diseases could improve the resolution of differential diagnoses.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004326
003      
CZ-PrNML
005      
20220127145335.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-021-90366-5 $2 doi
035    __
$a (PubMed)34035398
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Bruzova, Magdalena $u Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 14059, Prague 4 - Krc, Czech Republic
245    10
$a Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up / $c M. Bruzova, R. Rusina, Z. Stejskalova, R. Matej
520    9_
$a Various proteins play a decisive role in the pathology of different neurodegenerative diseases. Nonetheless, most of these proteins can only be detected during a neuropathological assessment, although some non-specific biomarkers are routinely tested for in the cerebrospinal fluid (CSF) as a part of the differential diagnosis of dementia. In antemortem CSF samples from 117 patients with different types of neuropathologically confirmed neurodegenerative disease with dementia, we assessed total-tau (t-tau), phosphorylated-tau (181P) (p-tau), amyloid-beta (1-42) (Aβ42), TAR DNA binding protein (TDP)-43, progranulin (PGRN), and neurofilament light (NfL) chain levels, and positivity of protein 14-3-3. We found t-tau levels and the t-tau/p-tau ratios were significantly higher in prion diseases compared to the other neurodegenerative diseases. Statistically significant differences in the t-tau/Aβ42 ratio predominantly corresponded to t-tau levels in prion diseases and Aβ42 levels in AD. TDP-43 levels were significantly lower in prion diseases. Additionally, the TDP-43/Aβ42 ratio was better able to distinguish Alzheimer's disease from other neurodegenerative diseases compared to using Aβ42 alone. In frontotemporal lobar degeneration, PRGN levels were significantly higher in comparison to other neurodegenerative diseases. There is an increasing need for biomarkers suitable for diagnostic workups for neurodegenerative diseases. It appears that adding TDP-43 and PGRN to the testing panel for neurodegenerative diseases could improve the resolution of differential diagnoses.
650    _2
$a proteiny 14-3-3 $x mozkomíšní mok $7 D048948
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a amyloidní beta-protein $x mozkomíšní mok $7 D016229
650    _2
$a pitva $7 D001344
650    _2
$a biologické markery $x mozkomíšní mok $7 D015415
650    _2
$a proteiny v mozkomíšním moku $x mozkomíšní mok $7 D002556
650    _2
$a DNA vazebné proteiny $x mozkomíšní mok $7 D004268
650    _2
$a demence $x mozkomíšní mok $x klasifikace $x diagnóza $7 D003704
650    _2
$a diferenciální diagnóza $7 D003937
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese $7 D005786
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neurofilamentové proteiny $x mozkomíšní mok $7 D016900
650    _2
$a peptidové fragmenty $x mozkomíšní mok $7 D010446
650    _2
$a progranuliny $x mozkomíšní mok $7 D000077153
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a proteiny tau $x mozkomíšní mok $7 D016875
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rusina, Robert $u Department of Neurology, 3rd Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Stejskalova, Zuzana $u Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 14059, Prague 4 - Krc, Czech Republic
700    1_
$a Matej, Radoslav $u Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 14059, Prague 4 - Krc, Czech Republic. radoslav.matej@ftn.cz $u Department of Pathology, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic. radoslav.matej@ftn.cz $u Department of Pathology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. radoslav.matej@ftn.cz
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 11, č. 1 (2021), s. 10837
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34035398 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145331 $b ABA008
999    __
$a ok $b bmc $g 1751710 $s 1155475
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 1 $d 10837 $e 20210525 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace